International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)

Abstract Background Real-world data on non-vitamin K oral anticoagulants (NOACs) are essential in determining whether evidence from randomised controlled clinical trials translate into meaningful clinical benefits for patients in everyday practice. RIVER (RIVaroxaban Evaluation in Real life setting)...

詳細記述

保存先:
書誌詳細
主要な著者: Jan Beyer-Westendorf, A. John Camm, Keith A. A. Fox, Jean-Yves Le Heuzey, Sylvia Haas, Alexander G. G. Turpie, Saverio Virdone, Ajay K. Kakkar, for the RIVER Registry Investigators
フォーマット: Artigo
言語:Inglês
出版事項: BMC 2019-04-01
シリーズ:Thrombosis Journal
主題:
Anticoagulant
Antithrombotic
Atrial fibrillation
Outcomes
Registry
Rivaroxaban
オンライン･アクセス:http://link.springer.com/article/10.1186/s12959-019-0195-7
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料